title: PSCA rs2294008 Polymorphism with Increased Risk of Cancer.
abstract: BACKGROUND
  Published data on the association between PSCA rs2294008 polymorphism and cancer risk have implicated inconclusive results. To determine the relationship and to precisely assess the effect size estimate of the association, we performed a meta-analysis.
  
  
  METHODS
  We searched published literature in Embase and PubMed databases using the search terms "PSCA", "prostate stem cell antigen", "variants", "polymorphism", "polymorphisms", and "cancer". A total of 21 eligible articles were retrieved, with 27, 197 cancer cases and 48, 237 controls.
  
  
  RESULTS
  On the whole, we found the association between PSCA rs2294008 polymorphism and cancer risk was statistically significant: TT vs CC: OR = 1.18, 95% CI, 1.10 to 1.27; TT + CT vs CC: OR = 1.08, 95% CI, 1.05 to 1.10; TT vs CT + CC: OR = 1.14, 95% CI, 1.07 to 1.21; T vs C: OR = 1.10, 95% CI, 1.06 to 1.14; CT vs CC: OR = 1.10, 95% CI, 1.06 to 1.13. Stratified analyses in cancer type and ethnicity showed similar results.
  
  
  CONCLUSIONS
  Based on the statistical evidence, we can draw a conclusion that the rs2294008 polymorphism of PSCA gene is likely to play a role in cancer carcinogenesis, especially in gastric cancer and bladder cancer.
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Peiliang
authors: P
authors: Geng
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Jianjun
authors: J
authors: Li
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Ning
authors: N
authors: Wang
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Juanjuan
authors: J
authors: Ou
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Ganfeng
authors: G
authors: Xie
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Chen
authors: C
authors: Liu
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Xiaoxin
authors: X
authors: Zhao
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Lisha
authors: L
authors: Xiang
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Yunmei
authors: Y
authors: Liao
authors: Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
authors: Houjie
authors: H
authors: Liang
mesh_terms: D006801:Humans; D000951:Antigens, Neoplasm / Q000235:genetics; D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease; D058851:GPI-Linked Proteins / Q000235:genetics; D009363:Neoplasm Proteins / Q000235:genetics; D009369:Neoplasms / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012307:Risk Factors
chemical_list: D000951:Antigens, Neoplasm; D058851:GPI-Linked Proteins; D009363:Neoplasm Proteins; C110843:PSCA protein, human